Weiss Multi Strategy Advisers LLC trimmed its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 61.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,500 shares of the biotechnology company’s stock after selling 4,000 shares during the period. Weiss Multi Strategy Advisers LLC’s holdings in bluebird bio were worth $248,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BLUE. Cornerstone Advisors Inc. raised its holdings in shares of bluebird bio by 1,540.0% during the fourth quarter. Cornerstone Advisors Inc. now owns 328 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 308 shares during the period. Exane Derivatives acquired a new stake in shares of bluebird bio during the fourth quarter worth $34,000. Belpointe Asset Management LLC acquired a new stake in shares of bluebird bio during the third quarter worth $110,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of bluebird bio by 36.6% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,104 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 296 shares during the period. Finally, NuWave Investment Management LLC increased its stake in bluebird bio by 14.4% in the 4th quarter. NuWave Investment Management LLC now owns 1,123 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 141 shares during the last quarter.

In other news, insider David Davidson sold 3,101 shares of bluebird bio stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $146.41, for a total value of $454,017.41. Following the completion of the transaction, the insider now owns 34,717 shares of the company’s stock, valued at approximately $5,082,915.97. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Nick Leschly sold 7,374 shares of bluebird bio stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $113.64, for a total transaction of $837,981.36. Following the completion of the transaction, the insider now directly owns 20,682 shares of the company’s stock, valued at approximately $2,350,302.48. The disclosure for this sale can be found here. In the last three months, insiders sold 42,438 shares of company stock valued at $5,486,744. Insiders own 3.00% of the company’s stock.

Several equities research analysts have issued reports on BLUE shares. Zacks Investment Research lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. ValuEngine lowered shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $161.00 price target (down from $250.00) on shares of bluebird bio in a research note on Wednesday, January 23rd. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a research note on Friday, January 11th. Finally, Piper Jaffray Companies lowered shares of bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $240.00 to $120.00 in a research note on Thursday, December 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $168.12.

Shares of BLUE opened at $146.64 on Friday. bluebird bio Inc has a one year low of $87.49 and a one year high of $199.70.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, beating analysts’ consensus estimates of ($2.83) by $0.11. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The company had revenue of $19.20 million during the quarter, compared to the consensus estimate of $9.06 million. During the same quarter last year, the firm posted ($2.52) EPS. The company’s quarterly revenue was up 357.1% on a year-over-year basis. As a group, equities analysts forecast that bluebird bio Inc will post -11.81 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/bluebird-bio-inc-blue-shares-sold-by-weiss-multi-strategy-advisers-llc/2912152.html.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Featured Article: Trading Ex-Dividend

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.